快速检索:        
    
在线办公系统
在线期刊
下载专区
排行榜
友情链接
扫描微信二维码,获取更多信息
朱小玉,张祥忠,钟雪云,林旭滨,陈运贤.参芪扶正注射液对血液恶性肿瘤化疗患者造血功能和免疫功能的影响[J].中国中西医结合杂志,2010,30(2):205-207
参芪扶正注射液对血液恶性肿瘤化疗患者造血功能和免疫功能的影响
Effect of Shenqi Fuzheng Injection for Hemopoietic and Immune Function Reconstruction in Patients with Hematologic Malignancies Undergoing Chemotherapy
免费下载全文  查看/发表评论  下载PDF阅读器
  
DOI:
中文关键词:  参芪扶正注射液  血液肿瘤  化疗  造血功能  免疫功能
英文关键词:Shenqi Fuzheng Injection  hematologic malignancies  chemotherapy  hemopoietic function  immune function
基金项目:
作者单位
朱小玉 中山大学附属第一医院血液内科 
张祥忠 安徽医科大学附属省立医院血液内科 
钟雪云 暨南大学医学院病理教研室 
林旭滨 中山大学附属肿瘤医院化疗科 
陈运贤 安徽医科大学附属省立医院血液内科 
摘要点击次数: 1853
全文下载次数: 805
中文摘要:
      目的研究参芪扶正注射液对血液系统恶性肿瘤化疗患者造血功能和免疫功能的影响。方法80例均处于初治诱导缓解治疗阶段的血液肿瘤患者,分为治疗组和对照组,治疗组在化疗的同时给予参芪扶正注射液250mL/(g.d),共14天,对照组单用化疗,两组其他支持治疗相同。观察两组化疗后缓解率,化疗前后血常规、T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)和B淋巴细胞(CD3-CD1+9)的水平。结果化疗后缓解率治疗组[90.0%(36/40)]与对照组[82.5%(33/40)]比较,差异无统计学意义(P>0.05);化疗后治疗组外周血白细胞计数和血红蛋白均高于对照组(P<0.05);CD3+、CD4+及CD4+/CD8+水平均明显高于对照组(P<0.05),CD3-CD1+9两组比较差异无统计学意义。结论参芪扶正注射液能减轻化疗对血液肿瘤患者骨髓造血功能的抑制,并能促进化疗患者骨髓造血功能的恢复;提高化疗患者的细胞免疫功能;改善血液肿瘤化疗患者的生活质量。
英文摘要:
      Objective To investigate the effect of Shenqi Fuzheng Injection (SFI) for hemopoietic and immune function reconstruction in patients with hematologic malignancies (HM) after chemotherapy. Methods Eighty HM patients at remission inducing stage of initial treatment were randomly assigned to two groups, the treatment group treated with SFI (250 mL daily) plus chemotherapy and the control group only treated with chemotherapy for 14 days, with same supportive treatments administered to both. Levels of blood routine test, T lymphocyte subsets (CD+3, CD+4, CD+4/CD+8) and B lymphocyte subsets CD-3CD+19 were determined before and after treatment, and the remission rate was assessed after treatment. Results The remission rates in the two groups showed no significant difference [90% (36/40) vs 82.5% (33/40), P>0.05] statistically. Levels of peripheral leucocyte count and hemoglobin as well as levels of CD+3, CD+4,CD+4/CD+8 were significantly higher in the treatment group than in the control group (P<0.05), but no significant difference was shown between groups in CD-3CD+19 level. Conclusion SFI can lighten the inhibition of chemotherapy on hemopoietic function of bone marrow, and promote its recovery, enhance the immune function, and improve the quality of life in patients with HM undergoing chemotherapy.
关闭